Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer

BACKGROUND AND PURPOSE: This single institution phase I trial determined the maximum tolerated dose (MTD) of concurrent vorinostat and capecitabine with radiation in non-metastatic pancreatic cancer. MATERIAL AND METHODS: Twenty-one patients received escalating doses of vorinostat (100–400 mg daily)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Radiother Oncol
Egile Nagusiak: Chan, Emily, Arlinghaus, Lori R., Cardin, Dana B., Goff, Laura, Berlin, Jordan D., Parikh, Alexander, Abramson, Richard G., Yankeelov, Thomas E., Hiebert, Scott, Merchant, Nipun, Bhaskara, Srividya, Chakravarthy, Anuradha Bapsi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4961249/
https://ncbi.nlm.nih.gov/pubmed/27106554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2016.04.013
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak